Subtopic Deep Dive
Clusterin in Prostate Cancer Progression
Research Guide
What is Clusterin in Prostate Cancer Progression?
Clusterin promotes prostate cancer progression by enhancing cell survival, metastasis via epithelial-mesenchymal transition, and resistance to androgen deprivation and chemotherapy.
Clusterin (CLU), a molecular chaperone, is upregulated in prostate cancer cells, conferring anti-apoptotic protection and treatment resistance (Trougakos et al., 2004; 204 citations). Studies show CLU mediates TGF-β-induced EMT and metastasis through Twist1 activation in prostate cancer models (Shiota et al., 2012; 155 citations). Clinical trials tested custirsen, a CLU antisense inhibitor, combined with docetaxel in metastatic castration-resistant prostate cancer (Saad et al., 2011; 127 citations). Over 10 key papers from 2000-2021 explore these mechanisms.
Why It Matters
Prostate cancer causes over 350,000 annual deaths worldwide, with resistance to androgen deprivation therapy (ADT) and chemotherapy driving progression to metastatic castration-resistant states. Clusterin inhibition with custirsen enhanced docetaxel efficacy in phase II trials for metastatic patients progressing after first-line therapy (Saad et al., 2011). CLU knockdown via siRNA induces apoptosis and sensitizes cells to genotoxic stress, suggesting therapeutic potential (Trougakos et al., 2004). Targeting CLU addresses EMT-mediated metastasis, as shown in TGF-β models (Shiota et al., 2012), offering strategies to overcome chemoresistance (Koltai, 2014).
Key Research Challenges
Therapeutic Targeting Specificity
Clusterin has two isoforms with opposing functions, complicating selective inhibition of the pro-cancerous secreted form (Koltai, 2014). Clinical trials with custirsen showed mixed efficacy in phase II for castration-resistant prostate cancer (Saad et al., 2011). Balancing anti-tumor effects without disrupting cytoprotective roles remains unresolved (Shannan et al., 2005).
Overcoming Chemoresistance Mechanisms
Clusterin confers resistance to docetaxel and mitoxantrone via anti-apoptotic pathways in prostate cancer (Saad et al., 2011). siRNA silencing sensitizes cells but translation to systemic delivery is challenging (Trougakos et al., 2004). Understanding CLU-lipidation in autophagy adds complexity (Zhang et al., 2014).
Elucidating EMT-Metastasis Role
Clusterin mediates TGF-β-induced EMT via Twist1, promoting prostate cancer invasion (Shiota et al., 2012). Validating this pathway across patient-derived models requires advanced in vivo studies. Integration with tumor microenvironment factors hinders progress (Marozzi et al., 2021).
Essential Papers
Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer
Batool Shannan, M. Seifert, Konstantin Leskov et al. · 2005 · Cell Death and Differentiation · 326 citations
Apolipoprotein J (clusterin) and Alzheimer's disease
Miguel Calero, Agueda Rostagno, Etsuro Matsubara et al. · 2000 · Microscopy Research and Technique · 249 citations
Apolipoprotein J (clusterin) is a ubiquitous multifunctional glycoprotein capable of interacting with a broad spectrum of molecules. In pathological conditions, it is an amyloid associated protein,...
Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress
Ioannis P. Trougakos, Alan So, Burkhard Jansen et al. · 2004 · Cancer Research · 204 citations
Abstract Clusterin/Apolipoprotein J (CLU) is a heterodimeric ubiquitously expressed secreted glycoprotein that is implicated in several physiological processes and is differentially expressed in ma...
Clusterin Mediates TGF-β–Induced Epithelial–Mesenchymal Transition and Metastasis via Twist1 in Prostate Cancer Cells
Masaki Shiota, Anousheh Zardan, Ario Takeuchi et al. · 2012 · Cancer Research · 155 citations
Abstract TGF-β promotes epithelial–mesenchymal transition (EMT) and induces clusterin (CLU) expression, linking these genes to cancer metastasis. CLU is a pleiotropic molecular chaperone that confe...
Clusterin: a key player in cancer chemoresistance and its inhibition
Tomas Koltai · 2014 · OncoTargets and Therapy · 149 citations
Clusterin is a heterodimeric disulfide-linked glycoprotein (449 amino acids) isolated in the rat prostate after castration. It is widely distributed in different tissues and highly conserved in spe...
The Molecular Chaperone Apolipoprotein J/Clusterin as a Sensor of Oxidative Stress: Implications in Therapeutic Approaches - A Mini-Review
Ioannis P. Trougakos · 2013 · Gerontology · 130 citations
<b><i>Background:</i></b> Organisms are constantly exposed to physiological and environmental stresses and therefore require an efficient surveillance of genome and proteome...
Clusterin Activates Survival through the Phosphatidylinositol 3-Kinase/Akt Pathway
Hayet Ammar, Jean Closset · 2008 · Journal of Biological Chemistry · 129 citations
Clusterin is, in its major form, a secreted heterodimeric disulfide-linked glycoprotein (75-80 kDa). It was first linked to cell death in the rat ventral prostate after androgen deprivation. Recent...
Reading Guide
Foundational Papers
Start with Shannan et al. (2005; 326 citations) for broad cancer context, then Trougakos et al. (2004; 204 citations) for siRNA evidence in cancer cells, followed by Shiota et al. (2012; 155 citations) for prostate-specific EMT mechanisms.
Recent Advances
Study Saad et al. (2011; 127 citations) for custirsen trials, Zhang et al. (2014; 122 citations) for autophagy links, and Koltai (2014; 149 citations) for chemoresistance inhibition strategies.
Core Methods
Core techniques include siRNA silencing (Trougakos et al., 2004), antisense oligonucleotides (Saad et al., 2011), TGF-β EMT assays (Shiota et al., 2012), and lipidation analysis (Zhang et al., 2014).
How PapersFlow Helps You Research Clusterin in Prostate Cancer Progression
Discover & Search
Research Agent uses searchPapers('clusterin prostate cancer progression') to retrieve 20+ papers including Shiota et al. (2012), then citationGraph to map influences from foundational Trougakos et al. (2004; 204 citations) to custirsen trials (Saad et al., 2011). findSimilarPapers expands to related EMT studies, while exaSearch uncovers hidden preprints on CLU inhibition.
Analyze & Verify
Analysis Agent employs readPaperContent on Shiota et al. (2012) to extract TGF-β-CLU-Twist1 mechanisms, then verifyResponse with CoVe against Saad et al. (2011) trial data for consistency. runPythonAnalysis processes citation networks or survival curves from custirsen trials using pandas for statistical verification, with GRADE grading CLU inhibition evidence as moderate due to phase II limitations.
Synthesize & Write
Synthesis Agent detects gaps like post-2014 custirsen phase III outcomes via gap detection, flags contradictions between CLU isoforms (Koltai, 2014). Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to integrate Trougakos et al. (2004), and latexCompile for review-ready PDFs; exportMermaid visualizes CLU-EMT signaling pathways.
Use Cases
"Extract survival data from custirsen prostate cancer trials and plot Kaplan-Meier curves"
Research Agent → searchPapers('custirsen prostate cancer') → Analysis Agent → readPaperContent(Saad et al. 2011) → runPythonAnalysis(pandas/matplotlib on trial endpoints) → researcher gets CSV-exported curves with p-values.
"Draft LaTeX review on clusterin-mediated EMT in prostate cancer"
Synthesis Agent → gap detection on Shiota et al. (2012) → Writing Agent → latexEditText(structured abstract) → latexSyncCitations(Trougakos 2004, Koltai 2014) → latexCompile → researcher gets compiled PDF with figure captions.
"Find open-source code for clusterin siRNA knockdown simulations"
Research Agent → searchPapers('clusterin siRNA prostate') → paperExtractUrls(Trougakos 2004) → paperFindGithubRepo → githubRepoInspect → researcher gets annotated code for apoptosis modeling with dependencies.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ clusterin prostate papers) → citationGraph → GRADE grading → structured report on progression mechanisms from Shannan (2005). DeepScan applies 7-step analysis with CoVe checkpoints to verify CLU's role in Saad et al. (2011) trials against Shiota (2012) EMT data. Theorizer generates hypotheses on CLU-autophagy links (Zhang 2014) for novel inhibitors.
Frequently Asked Questions
What defines clusterin overexpression in prostate cancer progression?
Clusterin upregulation promotes survival, EMT, and ADT resistance; siRNA silencing induces apoptosis and sensitizes cells (Trougakos et al., 2004).
What methods study clusterin's role?
siRNA knockdown (Trougakos et al., 2004), antisense oligonucleotides like custirsen (Saad et al., 2011), and TGF-β stimulation models assess EMT (Shiota et al., 2012).
What are key papers?
Shannan et al. (2005; 326 citations) reviews cancer roles; Trougakos et al. (2004; 204 citations) shows siRNA effects; Shiota et al. (2012; 155 citations) links to EMT.
What open problems exist?
Isoform-specific targeting, phase III custirsen validation beyond Saad et al. (2011), and microenvironment integration with CLU (Marozzi et al., 2021) remain unsolved.
Research Clusterin in disease pathology with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Clusterin in Prostate Cancer Progression with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Clusterin in disease pathology Research Guide